| Literature DB >> 17274610 |
Joachim Rudolph1, Libing Chen, Dyuti Majumdar, William H Bullock, Michael Burns, Thomas Claus, Fernando E Dela Cruz, Michelle Daly, Frederick J Ehrgott, Jeffrey S Johnson, James N Livingston, Robert W Schoenleber, Jeffrey Shapiro, Ling Yang, Manami Tsutsumi, Xin Ma.
Abstract
Compounds that simultaneously activate the three peroxisome proliferator-activated receptor (PPAR) subtypes alpha, gamma, and delta hold potential to address the adverse metabolic and cardiovascular conditions associated with diabetes and the metabolic syndrome. We recently identified the indanylacetic acid moiety as a well-tunable PPAR agonist head group. Here we report the synthesis and structure-activity relationship (SAR) studies of novel aryl tail group derivatives that led to a new class of potent PPAR pan agonists. While most of the tail group modifications imparted potent PPAR delta agonist activity, improvement of PPAR alpha and gamma activity required the introduction of new heterocyclic substituents that were not known in the PPAR literature. Systematic optimization led to the discovery of 4-thiazolyl-phenyl derivatives with potent PPAR alpha/gamma/delta pan agonistic activity. The lead candidate from this series was found to exhibit excellent ADME properties and superior therapeutic potential compared to known PPAR gamma activating agents by favorably modulating lipid levels in hApoA1 mice and hyperlipidemic hamsters, while normalizing glucose levels in diabetic rodent models.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17274610 DOI: 10.1021/jm061299k
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446